Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Statement of Comprehensive Income [Abstract]
Net loss	$ (19,352)	$ (16,168)
Other comprehensive loss:
Available for sale securities - net unrealized income (loss)	34	(4)
Total other comprehensive income (loss)	34	(4)
Comprehensive loss	(19,318)	(16,172)
Comprehensive income (loss) attributable to noncontrolling interests	9	(1)
Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (19,327)	$ (16,171)